Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File No. 001-12257 ______________________________ MERCURY GENERAL CORPORATION (Exact name of registrant as ...

Exhibit 99.2 Three months ended March 31, 2025 Supplemental Information of Gulfport Energy | Table of Contents: | Page: | | --- | --- | | Production Volumes by Asset Area | 2 | | Production and Pricing | 3 | | Consolidated Statements of Income | 4 | | Consolidated Balance Sheets | 5 | | Consolidated Statement of Cash Flows | 7 | | Reaffirmed 2025E Guidance | 8 | | Derivatives | 9 | | Non-GAAP Reconciliations | 10 | | Definitions | 10 | | Adjusted Net Income | 11 | | Adjusted EBITDA | 11 | | Adjusted Free Ca ...

Exhibit 99.1 1 Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance Highlights SALT LAKE CITY, May 6, 2025 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its first quarter ended March 31, 2025 and updated its previously issued financial guidance on business performance for the full-year 2025. "We had a challenging first quarter of 2025 with strength in our prenatal and onc ...

"In the first quarter of 2025, our focus on commercial execution resulted in total revenues of $898 million, led by the strong performance of Xywav and Epidiolex. In addition, our team continues to receive positive feedback from healthcare providers on the launch of Ziihera in its first approved indication of 2L HER2+ BTC. We are affirming our 2025 total revenue guidance range of $4.15 - $4.40 billion, reflecting our confidence in our commercial portfolio delivering top-line growth this year," said Bruce Co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 _______________________________________ HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ...

Exhibit 99.1 May 6, 2025 The AZEK Company Announces Second Quarter Fiscal 2025 Results; Reaffirms Fiscal Year 2025 Net Sales and Adjusted EBITDA Outlook Strong Second Quarter Performance Driven by Deck, Rail & Accessories Demand and Continued Margin Expansion Second Quarter Residential Sell-Through Growth Mid Single-Digits Year Over Year SECOND QUARTER FISCAL 2025 FINANCIAL HIGHLIGHTS REAFFIRMING FISCAL YEAR 2025 OUTLOOK AZEK provides certain of its outlook on a non-GAAP basis, as the Company cannot predict ...

Financial Performance - Total revenues for Q1 2025 were $1.53 billion, a decrease of 4% compared to $1.60 billion in Q1 2024[5] - Gross profit for Q1 2025 was $51 million, a 32% decrease from $75 million in Q1 2024[6] - Net income for Q1 2025 was $12 million, compared to a net loss of $6 million in Q1 2024[6] - Adjusted EBITDA for Q1 2025 was $21 million, a decrease of 29% from $29 million in Q1 2024[6] - Total revenues for Q1 2025 were $1,532,782, a decrease of 4.5% from $1,604,354 in Q1 2024[20] - Medical services revenue was $1,529,879, down from $1,601,195, reflecting a decline of 4.4% year-over-year[20] - Gross profit for Q1 2025 was $50,722, a decrease of 32.5% compared to $75,088 in Q1 2024[24] - Net income for Q1 2025 was $12,112, compared to a net loss of $6,034 in Q1 2024[20] - Adjusted EBITDA for Q1 2025 was $20,567, down from $29,054 in Q1 2024, representing a decline of 29.2%[30] Membership and Membership Trends - Medicare Advantage membership stood at 491,000, down 6% from 523,000 in the previous year[6] - Total members on the agilon platform decreased to 605,000, reflecting a 7% decline year-over-year[6] Guidance and Projections - The company reaffirmed its full-year 2025 earnings guidance, projecting total revenues between $5.85 billion and $6.025 billion[9] - For Q2 2025, total revenue guidance is set between $1.435 billion and $1.505 billion[9] Balance Sheet and Assets - The balance sheet as of March 31, 2025, included cash and marketable securities of $369 million and total debt of $35 million[8] - Total current assets increased to $1,650,722 in Q1 2025 from $1,457,774 in Q4 2024, marking an increase of 13.3%[18] - Total liabilities rose to $1,432,607 in Q1 2025 from $1,263,031 in Q4 2024, an increase of 13.4%[18] - Cash and cash equivalents at the end of Q1 2025 were $138,623, down from $188,231 at the end of Q4 2024, a decrease of 26.4%[18] Medical Margin and Expenses - Medical margin was $128 million, down 19% from $157 million in the same quarter last year[6] - Medical margin for Q1 2025 was $128,012, down from $157,353 in Q1 2024, a decline of 18.6%[29] - General and administrative expenses decreased to $65,956 in Q1 2025 from $76,422 in Q1 2024, a reduction of 13.6%[25] Definitions and Comparisons - Adjusted EBITDA is defined as net income adjusted to exclude various items, including interest expense and stock-based compensation[37] - Medical Margin is the most directly comparable GAAP measure to Gross Profit, while Adjusted EBITDA relates to Net Income[38] - Medical Margin and Adjusted EBITDA are used to identify underlying trends and evaluate operating performance over multiple periods[39]

Exhibit 99 Resideo Announces First Quarter 2025 Financial Results; Reaffirms 2025 Outlook SCOTTSDALE, Ariz., May 6, 2025 – Resideo Technologies, Inc. (NYSE: REZI), a leading global manufacturer, developer, and distributor of technology-driven sensing and controls products and solutions for residential and commercial end-markets, today announced financial results for the first quarter ended March 29, 2025. First Quarter 2025 Financial Highlights Management Remarks "Resideo had a strong first quarter, reporti ...

Exhibit 99.1 Qualys Announces First Quarter 2025 Financial Results Revenue Growth of 10% Year-Over-Year Raises 2025 Revenue Guidance to $648-$657 million FOSTER CITY, Calif., – May 6, 2025 – Qualys, Inc. (NASDAQ: QLYS), a leading provider of disruptive cloud-based IT, security and compliance solutions, today announced financial results for the first quarter ended March 31, 2025. For the quarter, the Company reported revenues of $159.9 million, net income under United States Generally Accepted Accounting Pri ...

Exhibit 99.1 Electronic Arts Reports Q4 and FY25 Results "Q4 marked a strong finish to FY25, with broad-based momentum across the portfolio positioning the business for accelerated growth," said Stuart Canfield, CFO of Electronic Arts. "As we enter FY26, we remain focused on disciplined execution as we build toward a slate of groundbreaking upcoming releases." Selected Operating Highlights and Metrics Selected Financial Highlights and Metrics Dividend EA has declared a quarterly cash dividend of $0.19 per s ...